Form 4: Atara Biotherapeutics Director Receives Restricted Stock Unit Grant Amidst Reverse Stock Split Adjustment

Atara Biotherapeutics, Inc. Director Carol Giltner Gallagher was granted 7,828 restricted stock units (RSUs) on June 10, 2025, bringing her total beneficial ownership to 33,012 shares, adjusted for a recent 1:25 reverse stock split.

Summary

• Carol Giltner Gallagher, a Director of Atara Biotherapeutics, Inc. (ATRA), acquired 7,828 shares in the form of Restricted Stock Units (RSUs) on June 10, 2025.
• These RSUs are set to vest on the earlier of June 10, 2026, or the date of the next annual meeting of stockholders, contingent upon Ms. Gallagher's continuous service.
• Following this transaction, Ms. Gallagher's total beneficial ownership of Atara Biotherapeutics common stock stands at 33,012 shares.
• The reported beneficial ownership amount of 33,012 shares reflects an adjustment due to a 1:25 reverse stock split implemented by Atara Biotherapeutics on June 20, 2024.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing (Form 4) reporting an insider transaction. It provides factual information about a director's equity grant and the impact of a reverse stock split, without expressing positive or negative sentiment regarding company performance or outlook.

Positives

• The grant of Restricted Stock Units (RSUs) to a director aligns their interests with those of shareholders, as the value of their compensation is tied to the company's stock performance.
• The acquisition of additional equity by a director can signal confidence in the company's future prospects.

Future Outlook

The 7,828 Restricted Stock Units granted to Director Carol Giltner Gallagher are scheduled to vest on the earlier of June 10, 2026, or the date of the next annual meeting of stockholders, subject to her continuous service.

Industry Context

The grant of Restricted Stock Units (RSUs) to directors is a common practice in the biotechnology and pharmaceutical industries, serving as a form of equity compensation to attract and retain talent while aligning management and director interests with long-term shareholder value. Reverse stock splits, such as the 1:25 split by Atara Biotherapeutics, are often undertaken by companies to increase their stock price, potentially to meet exchange listing requirements or improve market perception, though the specific reasons are not detailed in this filing.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to a director is a standard compensation practice across publicly traded companies, including those in the biotechnology sector, aligning director incentives with company performance.
• The vesting schedule tied to continuous service and a specific future date or event (annual meeting) is typical for RSU grants in the industry.
• Reverse stock splits are not uncommon for companies, particularly in the biotech sector, that may experience significant stock price volatility or trade at lower price points, aiming to increase per-share value and potentially broaden investor appeal or maintain exchange listing compliance.

Corporate Governance

Related Party Transactions

• The grant of 7,828 Restricted Stock Units (RSUs) to Carol Giltner Gallagher, a Director of Atara Biotherapeutics, Inc., constitutes a related party transaction as it involves the company providing equity compensation to an insider.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's incentives with shareholder interests, potentially leading to better long-term decision-making. The reverse stock split impacts the number of shares held and the per-share price, which can affect investor perception and liquidity.
• Employees: While not directly impacting all employees, the compensation structure for directors can reflect broader corporate compensation philosophies.

Next Steps

• Vesting of the 7,828 Restricted Stock Units on the earlier of June 10, 2026, or the date of the next annual meeting of stockholders, subject to continuous service.

Key Dates

Keywords

Atara Biotherapeutics, ATRA, Form 4, Insider Transaction, Restricted Stock Units, RSU, Director Compensation, Stock Ownership, Reverse Stock Split, Corporate Governance